Therapeutic Solutions International Reports Superior Efficacy of ApoptoCyte™ on Chronic Obstructive Pulmonary Disease Model Compared to Conventional Stem Cell Approaches

Rhea-AI Summary

Therapeutic Solutions International (OTC-PINK: TSOI) announced promising findings from its research on the ApoptoCyte™ procedure, which showed superior efficacy in treating Chronic Obstructive Pulmonary Disease (COPD) with its JadiCell™ product. In comparative studies, the ApoptoCyte-treated JadiCell exhibited the highest therapeutic activity against COPD in an animal model. The company is preparing for a Phase III clinical trial for COPD treatment, leveraging existing IND #28508, and aims to address significant unmet medical needs in this area.

Positive

• Demonstrated superior efficacy of ApoptoCyte treated JadiCell for COPD.
• Phase III clinical trial planned for advanced COVID-19, showcasing ongoing research commitment.
• Possession of IND #28508 enables further development for COPD treatment.

Negative

• Dependency on FDA discussions for initiating the clinical trial.

Phase III Clinical Stage Company Demonstrates Superior Efficacy of Proprietary Stem Cell Apoptotic Body Based Drug

ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International announced today new data demonstrating superior effects of the Company’s ApoptoCyte™ procedure treated JadiCell™ product compared to other stem cells in treating an animal model of Chronic Obstructive Pulmonary Disease (COPD).

In a series of experiments, mice were administered the enzyme elastase to mimic COPD. It was shown that untreated JadiCell stem cells, as well as stem cells from sources conventionally utilized, specifically fat and bone marrow, had some therapeutic activity including reduction of inflammation, stimulation of regenerative growth factors, and preservation of alveoli structure¹. All cell types had improved therapeutic activity when processed using the ApoptoCyte procedure, with JadiCell possessing the highest activity.

“In May of this year we announced and filed a patent on the ApoptoCyte procedure which involves the induction of cellular suicide in the stem cell, extraction of small vesicles called “apoptotic bodies” and co-administration with specific drugs such as certain histone deacetylase (HDAC) inhibitors. Leveraging this technology, we have filed a new patent on COPD which contains the data disclosed today,” said Dr. James Veltmeyer, Chief Medical Officer of the Company, and co-inventor of both patents. “The demonstration that the ApoptoCyte Procedure is applicable to COPD, which is one of the major causes of death in the world, is extremely exciting.”

The Company possesses IND #28508 for using non-modified JadiCells for COPD, however the clinical trial is expected to initiate following further discussions between the Company and the FDA. Additionally, the Company currently is running a Phase III clinical trial using JadiCells for treatment of advanced COVID-19 infection.

“COPD represents a significant unmet medical need for which no curative approaches exist,” said Timothy Dixon, President, and CEO of the Company and co-inventor of the patents. “We are grateful to have a team of cellular and COPD experts who have assisted us in creating what we believe is a first in class approach to treating COPD. We hope to continue exploring the applicability of the ApoptoCyte Procedure in other therapeutics in the regenerative medicine space.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

¹ Therapeutic Solutions International Announces ApoptoCyte Procedure for Enhancing Stem Cell Activity | BioSpace

View source version on businesswire.com: https://www.businesswire.com/news/home/20220812005201/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International, Inc.

FAQ

What are the latest findings from Therapeutic Solutions International regarding COPD treatment?

The company announced that its ApoptoCyte procedure significantly enhances the efficacy of JadiCell treatment for COPD in animal models.

What is the ticker symbol for Therapeutic Solutions International?

The ticker symbol for Therapeutic Solutions International is TSOI.

Is Therapeutic Solutions International planning any clinical trials for COPD?

Yes, Therapeutic Solutions International is preparing to initiate a Phase III clinical trial for COPD treatment.

What does the ApoptoCyte™ procedure do?

The ApoptoCyte™ procedure induces cellular apoptosis in stem cells, enhancing their therapeutic efficacy.

When was the ApoptoCyte procedure patent filed?

The patent was filed in May of this year.